Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
63 pending office actions • 30 art units • 60 examiners • 0 of 63 (0%) have an AI response strategy ready • 40 patents granted in the last 365 days
Pfizer Inc. currently manages 58 pending office actions within the Biotechnology & Pharmaceuticals technology area. This volume of work is spread across 28 distinct art units, demonstrating the scientific scope of the company's current patent applications. The prosecution is decentralized, involving 57 distinct examiners. This means that nearly every one of the 58 pending office actions is being reviewed by a different individual, requiring an adaptable prosecution strategy.
FOLEY, SHANON A is identified as the busiest examiner, yet this individual is responsible for only 2 pending office actions. This low concentration of cases per examiner, where 57 distinct examiners handle 58 pending office actions, suggests that Pfizer's outcomes are subject to the individual interpretations of a large group of patent office personnel. Navigating 28 distinct art units further defines the landscape, as it involves a wide array of specialized examination groups within the biotechnology and pharmaceutical sectors.
Based on the USPTO statutory response window for each pending office action. 22 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 22 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 8 (13%) |
| §103 only | 11 (17%) |
| §102 only | 2 (3%) |
| §112 only | 9 (14%) |
| Double-patenting only | 3 (5%) |
| Double-patenting + other | 9 (14%) |
| Multi-statute (no §101) | 19 (30%) |
| No statute on record | 2 (3%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MCDOWELL, BRIAN E | 2 | 74.1% | +30.8% |
| FOLEY, SHANON A | 2 | 73.3% | +18.1% |
| BORALSKY, LUKE ALAN | 2 | 66.7% | +44.4% |
| MASTERS, KRISTEN MICHELLE | 1 | 64.7% | +24.1% |
| KIFLE, BRUCK | 1 | 79.2% | +15.9% |
| LEE, SIN J | 1 | 68.8% | +25.1% |
| KIM, SAMUEL CHONG | 1 | 48.7% | +70.4% |
| VAJDA, KRISTIN ANN | 1 | 84.0% | +10.9% |
| ZOU, NIANXIANG | 1 | 64.1% | +24.8% |
| MPAMUGO, CHINYERE | 1 | 28.5% | +26.9% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18789272 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | VAJDA, KRISTIN ANN | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17431462 | Methods for purifying bacterial polysaccharides | CREWS, JARET JAMES | 53d overdue |
| 18322395 | PURIFICATION OF ANTIBODY DRUG CONJUGATES USING A SODIUM PHOSPHATE GRADIENT | HAMA, JOANNE | 17d overdue |
| 18565626 | METHODS OF TREATMENT | VALENROD, YEVGENY | 17d overdue |
| 18347698 | SELF-AMPLIFYING RNA ENCODING AN INFLUENZA VIRUS ANTIGEN | CHEN, STACY BROWN | 8d overdue |
| 18255869 | METHODS AND COMPOSITIONS FOR INHIBITING EXCESS NUCLEIC ACID PRECIPITATION | TSAY, MARSHA M | 2d overdue |
| 18557987 | VACCINATION AGAINST BACTERIAL AND BETACORONAVIRUS INFECTIONS | FOLEY, SHANON A | 8d |
| 18551038 | PHARMACEUTICAL COMPOSITIONS CONTAINING ADENO-ASSOCIATED VIRAL VECTOR | VIVLEMORE, TRACY ANN | 9d |
| 19196858 | METHOD AND APPARATUS FOR IMPROVED MAN-MACHINE INTERACTIONS | MASTERS, KRISTEN MICHELLE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18557987 | VACCINATION AGAINST BACTERIAL AND BETACORONAVIRUS INFECTIONS | FOLEY, SHANON A | 8d |
| 19196858 | METHOD AND APPARATUS FOR IMPROVED MAN-MACHINE INTERACTIONS | MASTERS, KRISTEN MICHELLE | — |
| 18954736 | Crystalline form of (2R)-2-(5-fluoro-2-methoxypyridin-4-yl)-1-[(2S)-7-methyl-6-(pyrimidin-2-yl)-3,4-dihydro-1H-spiro[1,8-naphthyridine-2,3-pyrrolidin]-1-yl]propan-1-one | KIFLE, BRUCK | — |
| 18825795 | AQUEOUS FORMULATION COMPRISING 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-DIMORPHOLIN-4-YL-1,3,5-TRIAZIN-2-YL)PHENYL]UREA | LEE, SIN J | — |
| 18842257 | COMPUTERIZED DECISION SUPPORT TOOL AND MEDICAL DEVICE FOR RESPIRATORY CONDITION MONITORING AND CARE | KIM, SAMUEL CHONG | — |
| 18789272 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | VAJDA, KRISTIN ANN | — |
| 18833823 | CORONAVIRUS ANTIGEN VARIANTS | ZOU, NIANXIANG | — |
| 18772655 | Pyrrolo[2,3-d]pyrimidinyl, Pyrrolo[2,3-b]pyrazinyl and Pyrrolo[2,3-d]pyridinyl Acryla-mides | MCDOWELL, BRIAN E | — |
| Art Unit | Apps |
|---|---|
| 1624 | 4 |
| 1622 | 4 |
| 1645 | 3 |
| 1691 | 3 |
| 1631 | 3 |
| 1674 | 2 |
| 1621 | 2 |
| 1671 | 2 |
| 1626 | 2 |
| 1656 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19196858 | METHOD AND APPARATUS FOR IMPROVED MAN-MACHINE INTERACTIONS | MASTERS, KRISTEN MICHELLE | — | §101§103 | Non-Final OA | — | Pending | May 02, 2025 |
| 18954736 | Crystalline form of (2R)-2-(5-fluoro-2-methoxypyridin-4-yl)-1-[(2S)-7-methyl-6-(pyrimidin-2-yl)-3,4-dihydro-1H-spiro[1,8-naphthyridine-2,3-pyrrolidin]-1-yl]propan-1-one | KIFLE, BRUCK | — | DP | Non-Final OA | — | Pending | Nov 21, 2024 |
| 18825795 | AQUEOUS FORMULATION COMPRISING 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-DIMORPHOLIN-4-YL-1,3,5-TRIAZIN-2-YL)PHENYL]UREA | LEE, SIN J | — | §103DP | Non-Final OA | — | Pending | Sep 05, 2024 |
| 18842257 | COMPUTERIZED DECISION SUPPORT TOOL AND MEDICAL DEVICE FOR RESPIRATORY CONDITION MONITORING AND CARE | KIM, SAMUEL CHONG | — | §101§103§112 | Non-Final OA | — | Pending | Aug 28, 2024 |
| 18789272 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | VAJDA, KRISTIN ANN | 1624 | DP | Non-Final OA | — | Pending | Jul 30, 2024 |
| 18833823 | CORONAVIRUS ANTIGEN VARIANTS | ZOU, NIANXIANG | — | §101§102§103 | Non-Final OA | — | Pending | Jul 26, 2024 |
| 18772655 | Pyrrolo[2,3-d]pyrimidinyl, Pyrrolo[2,3-b]pyrazinyl and Pyrrolo[2,3-d]pyridinyl Acryla-mides | MCDOWELL, BRIAN E | — | §112Other | Non-Final OA | — | Pending | Jul 15, 2024 |
| 18722084 | DIGITAL MEDICINE COMPANION FOR TREATING AND MANAGING SKIN DISEASES | MPAMUGO, CHINYERE | 3685 | §101§103 | Non-Final OA | — | Pending | Jun 20, 2024 |
| 18739401 | POLYNUCLEOTIDE COMPOSITIONS AND USES THEREOF | OGUNBIYI, OLUWATOSIN A | 1645 | §102§103§112 | Non-Final OA | — | Pending | Jun 11, 2024 |
| 18714642 | CDK4 INHIBITOR FOR THE TREATMENT OF CANCER | TOWNSLEY, SARA ELIZABETH | — | §103§112DP | Non-Final OA | — | Pending | May 30, 2024 |
| 18713747 | MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF | ELENISTE, PIERRE PAUL | — | §112 | Non-Final OA | — | Pending | May 28, 2024 |
| 18708093 | Enhancement Of CD47 Blockade Therapy With Anti-VEGF Agents | HOLTZMAN, KATHERINE ANN | — | §101§102§103§112DP | Non-Final OA | — | Pending | May 07, 2024 |
| 18706732 | METHODS OF TREATING MITOCHONDRIAL MYOPATHIES USING ANTI-GDF15 ANTIBODIES | ABBAS, SYED JARAR | 1674 | §103§112DP | Non-Final OA | — | Pending | May 01, 2024 |
| 18699159 | IMMUNOGENIC LNP COMPOSITIONS AND METHODS THEREOF | FOLEY, SHANON A | — | §102§103§112 | Non-Final OA | — | Pending | Apr 05, 2024 |
| 18621962 | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | GANGLE, BRIAN J | 1691 | §102§112DP | Non-Final OA | — | Pending | Mar 29, 2024 |
| 18249752 | METHODS FOR MEASURING DYSTROPHIN IN TISSUE SAMPLES | SODERQUIST, ARLEN | — | §102§103§112 | Non-Final OA | — | Pending | Feb 28, 2024 |
| 18586896 | CETYLTRIMETHYLAMMONIUM BROMIDE (CTAB) AS A LYSIS AND FLOCCULATION REAGENT IN GENE THERAPY DOWNSTREAM PROCESSES | KARUNASENA, ENUSHA | — | §102§103§112 | Non-Final OA | — | Pending | Feb 26, 2024 |
| 18684225 | Amorphous Form of (S)-2-(5-((3-Ethoxypyridin-2-YL)Oxy)Pyridin-3-YL)-N-(Tetrahydrofuran-3-YL)Pyrimidine-5-Carboxamide | YOO, SUN JAE | 1621 | §112 | Non-Final OA | — | Pending | Feb 16, 2024 |
| 18442988 | BTLA Fusion Protein Agonists and Uses Thereof | BUNNER, BRIDGET E | — | §102§103§112DP | Non-Final OA | — | Pending | Feb 15, 2024 |
| 18541015 | HSD17B13 Inhibitors and/or Degraders | BORALSKY, LUKE ALAN | 1624 | §102§103§112 | Non-Final OA | — | Pending | Dec 15, 2023 |
| 18535116 | IMMUNOGENIC COMPOSITIONS AND METHODS FOR ELICITING AN IMMUNE RESPONSE AGAINST CLOSTRIDIOIDES (CLOSTRIDIUM) DIFFICILE | HAUK TEODORO, PRICILA NMN | 1645 | §103DP | Final Rejection | 34d | Pending | Dec 11, 2023 |
| 18532424 | Papain-like protease (PLpro) inhibitors | BELL, SARA ELIZABETH | 1625 | §102§112 | Non-Final OA | — | Pending | Dec 07, 2023 |
| 18557987 | VACCINATION AGAINST BACTERIAL AND BETACORONAVIRUS INFECTIONS | FOLEY, SHANON A | 1671 | §103§112 | Final Rejection | 8d | Pending | Oct 30, 2023 |
| 18555058 | COMBINATION THERAPY COMPRISING A PKC INHIBITOR AND A MEK INHIBITOR | O DELL, DAVID K | 1621 | §103 | Non-Final OA | 5d | Pending | Oct 12, 2023 |
| 18552453 | Ether-Linked Antiviral Compounds | ANDERSON, REBECCA L | 1626 | §112 | Non-Final OA | 71d overdue | Pending | Sep 26, 2023 |
| 18551619 | METHODS FOR PRODUCING OF LIPIDS | CARR, DEBORAH D | 1691 | §103§112 | Non-Final OA | — | Pending | Sep 21, 2023 |
| 18551038 | PHARMACEUTICAL COMPOSITIONS CONTAINING ADENO-ASSOCIATED VIRAL VECTOR | VIVLEMORE, TRACY ANN | 1638 | §102§103§112Other | Non-Final OA | 9d | Pending | Sep 18, 2023 |
| 18550326 | Methods For Treatment of Vitiligo | FERGUSON, JALISA HOLMES | 1626 | §102§103§112 | Non-Final OA | — | Pending | Sep 13, 2023 |
| 18549158 | Treatment of Breast Cancer with Amcenestrant and Palbociclib | LEESER, ERICH A | 1622 | §103 | Non-Final OA | 22d | Pending | Sep 05, 2023 |
| 18277425 | NOVEL DRUGGABLE REGIONS IN THE HUMAN CYTOMEGALOVIRUS GLYCOPROTEIN B POLYPEPTIDE AND METHODS OF USE THEREOF | CORNELIUS, CLAIRE ADRIENNE | 1618 | §101§102§112 | Non-Final OA | — | Pending | Aug 16, 2023 |
| 18350986 | CELLS AND METHOD OF CELL CULTURE | HUMPHRIES, NICHOLAS ADAM | 1631 | §103 | Final Rejection | 60d overdue | Pending | Jul 12, 2023 |
| 18347698 | SELF-AMPLIFYING RNA ENCODING AN INFLUENZA VIRUS ANTIGEN | CHEN, STACY BROWN | 1672 | §103§112 | Final Rejection | 8d overdue | Pending | Jul 06, 2023 |
| 18343968 | NEISSERIA MENINGITIDIS COMPOSITIONS AND METHODS THEREOF | DEVI, SARVAMANGALA | 1645 | — | Final Rejection | — | Pending | Jun 29, 2023 |
| 18268959 | SOLID FORMS OF A CDK2 INHIBITOR | MCDOWELL, BRIAN E | 1624 | §112 | Final Rejection | — | Pending | Jun 21, 2023 |
| 18258027 | IMPROVED PHARMACEUTICAL COMPOSITIONS CONTAINING ADENO-ASSOCIATED VIRAL VECTOR | RIGA, MICHAEL ANGELO | 1634 | §102§103§112 | Non-Final OA | — | Pending | Jun 16, 2023 |
| 18257215 | HILIC UPLC-MS Method For Separating and Analyzing Intact Adeno-Associated Virus Capsid Proteins | LY, KRISTINA ELISABETH | 1671 | §103§112 | Non-Final OA | — | Pending | Jun 13, 2023 |
| 18255869 | METHODS AND COMPOSITIONS FOR INHIBITING EXCESS NUCLEIC ACID PRECIPITATION | TSAY, MARSHA M | 1656 | §101§102§103 | Non-Final OA | 2d overdue | Pending | Jun 04, 2023 |
| 18322395 | PURIFICATION OF ANTIBODY DRUG CONJUGATES USING A SODIUM PHOSPHATE GRADIENT | HAMA, JOANNE | 1647 | §103§112Other | Non-Final OA | 17d overdue | Pending | May 23, 2023 |
| 18250570 | CRYSTAL-FREE HIGH-CONCENTRATION TESTOSTERONE CYPIONATE FORMULATIONS | MITCHELL, EDWIN COLEMAN | 1619 | §103 | Final Rejection | 26d overdue | Pending | Apr 26, 2023 |
| 18249581 | PEG-FREE AQUEOUS SUSPENSIONS FOR PARENTERAL ADMINISTRATION OF A CORTICOSTEROID | AGGARWAL, SAHIL CHANDER | 1623 | §103 | Non-Final OA | — | Pending | Apr 19, 2023 |
| 18249411 | Methods for purifying bacterial polysaccharides | PATEL, PRANAV N | 1777 | §112 | Final Rejection | 29d | Pending | Apr 18, 2023 |
| 18042561 | GROUP B STREPTOCOCCUS POLYSACCHARIDE-PROTEIN CONJUGATES, METHODS FOR PRODUCING CONJUGATES, IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATES, AND USES THEREOF | JACKSON-TONGUE, LAKIA J | 1600 | DP | Final Rejection | — | Pending | Feb 22, 2023 |
| 18041447 | Methods of Protecting RNA | BATES, KEENAN ALEXANDER | 1631 | §112 | Final Rejection | — | Pending | Feb 13, 2023 |
| 18004109 | Preparation Of A Pyrimidinyl-3,8-Diazabicyclo[3.2.1]Octanylmethanone Derivative And Salt Thereof | MOORE, SUSANNA | 1624 | §102Other | Non-Final OA | 36d overdue | Pending | Jan 03, 2023 |
| 18146014 | COMBINATION OF AN ANTI-PD-L1 ANTIBODY AND A DNA-PK INHIBITOR FOR THE TREATMENT OF CANCER | JOHANSEN, PETER N. | 1644 | §103DP | Non-Final OA | 85d overdue | Pending | Dec 23, 2022 |
| 18002555 | COMPUTERIZED DECISION SUPPORT TOOL AND MEDICAL DEVICE FOR SCRATCH DETECTION AND FLARE PREDICTION | WESTFALL, SARAH ANN | 3791 | §103 | Non-Final OA | — | Pending | Dec 20, 2022 |
| 18002368 | METHOD OF TREATMENT OF INFLAMMATORY BOWEL DISEASE USING ANTI-TL1A ANTIBODIES | KAUFMAN, CLAIRE M | 1674 | §103§112 | Non-Final OA | — | Pending | Dec 19, 2022 |
| 17997312 | MODIFIED NUCLEIC ACIDS ENCODING ASPARTOACYLASE (ASPA) AND VECTOR FOR GENE THERAPY | ALLEN, SARAH ELIZABETH | 1637 | Other | Non-Final OA | 34d | Pending | Oct 27, 2022 |
| 17799992 | PURIFICATION OF SACCHARIDES | LAU, JONATHAN S | 1693 | §102§103 | Final Rejection | — | Pending | Aug 16, 2022 |
| 17607341 | REAL-TIME TRACKING AND MANAGEMENT OF STANDARD WORKFLOWS | KONERU, SUJAY | 3624 | §101§103 | Non-Final OA | — | Pending | Oct 28, 2021 |
| 17431462 | Methods for purifying bacterial polysaccharides | CREWS, JARET JAMES | 1691 | §103§112 | Final Rejection | 53d overdue | Pending | Aug 17, 2021 |
| 17299180 | Cells with reduced inhibitor production and methods of use thereof | SPANGLER, JOSEPH RANKIN | 1656 | §103 | Final Rejection | — | Pending | Jun 02, 2021 |
| 17278866 | SSI CELLS WITH PREDICTABLE AND STABLE TRANSGENE EXPRESSION AND METHODS OF FORMATION | LEONARD, ARTHUR S | 1631 | §103§112 | Non-Final OA | — | Pending | Mar 23, 2021 |
| 18830475 | TABLETS COMPRISING 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDE | BAEK, BONG-SOOK | — | §103Other | Non-Final OA | — | Pending | Sep 10, 2024 |
| 18717181 | METHODS OF ADMINISTERING A MODULATOR OF HEMOGLOBIN | BORALSKY, LUKE ALAN | — | §102§103§112DP | Non-Final OA | — | Pending | Jun 06, 2024 |
| 17777909 | METHODS OF ADMINISTERING VOXELOTOR | SANCHEZ, JUSTIN CHRISTOPHER | 1622 | §102 | Final Rejection | 29d | Pending | May 18, 2022 |
| 18841455 | NOVEL S1P1 RECEPTOR AGONIST, CRYSTALLINE SALTS, PROCESSES FOR PREPARING, AND USES RELATED THERETO | AULAKH, CHARANJIT | — | §112 | Non-Final OA | — | Pending | Aug 26, 2024 |
| 18441209 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | SAWYER, JENNIFER C | 1658 | §112 | Non-Final OA | — | Pending | Feb 14, 2024 |
| 18566862 | Administration of a Compound to Individuals with Hepatic Impairment | TRAN, ERIC | 1629 | §103Other | Non-Final OA | 12d | Pending | Dec 04, 2023 |
| 18524124 | METHODS OF TREAMENT | INAM, SAHAR | 1622 | §103 | Non-Final OA | 30d overdue | Pending | Nov 30, 2023 |
| 18565626 | METHODS OF TREATMENT | VALENROD, YEVGENY | 1628 | §103§112 | Final Rejection | 17d overdue | Pending | Nov 30, 2023 |
| 18259843 | Methods of Treatment | ABDALHAMEED, MANAHIL MIRGHANI ALI | 1622 | §103DPOther | Non-Final OA | 71d | Pending | Jun 29, 2023 |
| 17787454 | SURFACE MODIFYING COATING FOR MEDICAL DEVICES | VASISTH, VISHAL V | 1771 | §103 | Final Rejection | 19d | Pending | Jun 20, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial